
- Psychiatric Times Vol 28 No 4
- Volume 28
- Issue 4
Introduction: Looking to the Future of Psychopharmacology
The focus of this Special Report is on some future-oriented aspects of psychopharmacology. First, it is an eclectic set of articles that cover treating resistant depression, using currently illegal drugs to treat psychiatric problems, and finally the potential of using vaccines to treat substance use disorders.
The focus of this Special Report is on some future-oriented aspects of psychopharmacology. First, it is an eclectic set of articles that cover treating resistant depression, using currently illegal drugs to treat psychiatric problems, and finally the potential of using vaccines to treat substance use disorders. Frankly, each of these topics can fill its own Special Report.
One of the considerations in a discussion of the ethics of psychopharmacology is the use of brand-name, expensive drugs versus generics. Sometimes the generics are not equal; there may be a 30% sway in bioavailability between the brand-name drug and available generics. The slow-release technology also differs from brand name to generics and allows for differential adverse-effect issues in practice. This must be weighed against the clear cost difference. Monotherapy approaches are the FDA norm and are speci-fied as first-line treatments in most guidelines. However, monotherapy does not often yield true remission of symptoms.
Polypharmacy certainly drives up cost and adverse effects, but it appears to be more of the norm in clinical practice despite a relative lack of empirical evidence that polypharmacy is inherently more effective. One could discuss off-label prescribing and the use of this rational polypharmacy approach. Does the FDA approval process that ultimately allows advertising provide enough evidence to move more risky drugs into early treatment phases in guidelines instead of using less risky agents that have less empirical data?
Should unipolar antidepressants be used in bipolar, depressed patients? There is an increased risk of manic escalation with formal antidepressants; however, they seem to be devoid of the risk of movement disorders and severe metabolic disor-ders that are possible adverse effects of the current bipolar depression–approved atypical antipsychotics. Perhaps we will find nonmonoamine, nonmania-escalating bipolar depression drugs in the research pipeline. In their article,
The article by
Upcoming in Part 2
In Part 2 of the Special Report coming in the May 2011 issue of Psychiatric Times,
The availability of psychotropic medications has improved the lives of millions of patients with severe mental illness. However, the increased use of these medications has created ethical and societal concerns.
Articles in this issue
over 14 years ago
Custom-Made Neural Stem Cellsover 14 years ago
The Judaic Foundations of Cognitive-Behavioral Therapyover 14 years ago
Expert Witnessover 14 years ago
Data Breach Insuranceover 14 years ago
Risk Analysis: Tips for Health Care Practitionersover 14 years ago
Antipsychotics and the Shrinking Brainover 14 years ago
Novel Treatment Avenues for Bipolar Depressionover 14 years ago
Antidrug VaccinesNewsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.